Sofia Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sofia Ferreira has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Laura Donatella Attardi
Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
56 shared publications - Kha The Nguyen
Department of Radiation Oncology, Division of Radiation and Cancer Biology, Stanford University School of Medicine, Stanford, USA
43 shared publications - Alyssa M. Kaiser
Calico Life Sciences
42 shared publications - Arati Rajeevan
Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
42 shared publications - Arielle Elkrief
Axe cancer, Centre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada
42 shared publications - Christopher T. Chen
Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Palo Alto, CA, USA
42 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Identification of 4 groups within TCGA PAAD data.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Identification of 4 groups within TCGA PAAD data.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Phenotypes in acinar cell of origin Arf knockout and double Arf and Trp53 knockout mouse cohorts
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Phenotypes in acinar cell of origin Arf knockout and double Arf and Trp53 knockout mouse cohorts
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Analysis of PDAC development from adult mouse acinar cells across different Arf and Trp53 genotypes
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Analysis of PDAC development from adult mouse acinar cells across different Arf and Trp53 genotypes
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
CDKN2A alterations are common in mouse KTC PDACs.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
CDKN2A alterations are common in mouse KTC PDACs.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Expression of Ink4a and a p53 tumor suppression-associated gene (TSAG) signature
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Expression of Ink4a and a p53 tumor suppression-associated gene (TSAG) signature
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Transcriptome analysis of PDACs from KTC, KTC;Trp53fl/fl, KTC;Arffl/fl and KTC;Trp53fl/fl; Arffl/fl mice
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Transcriptome analysis of PDACs from KTC, KTC;Trp53fl/fl, KTC;Arffl/fl and KTC;Trp53fl/fl; Arffl/fl mice
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Summary of types of mutations found in CDKN2AARF and CDKN2AINK4A in Group 1 to 4 PDACs.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
Summary of types of mutations found in CDKN2AARF and CDKN2AINK4A in Group 1 to 4 PDACs.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
The CDKN2A locus, which is frequently deleted in pancreatic ductal adenocarcinoma (PDAC), encodes two tumor suppressors, ARF and INK4A, that may influence tumorigenesis through distinct mechanisms. Distinguishing their individual contributions to cancer could help improve the understanding of PDAC pathogenesis and potentially uncover targetable vulnerabilities. Moreover, whereas ARF is known to enhance p53 function, defining its p53-independent activities could elucidate new processes that drive PDAC development. In this study, we sought to understand ARF function in PDAC suppression. Analysis of gene expression and mutational patterns in human PDAC TCGA data indicated that CDKN2AARF and CDKN2AINK4A are commonly both affected by point mutations and/or deletions, suggesting that their combined inactivation contributes to PDAC development. In genetically engineered mouse models, Arf inactivation accelerated KRASG12D-driven PDAC development, both in the presence and absence of Trp53, demonstrating that ARF is a PDAC-suppressor and can act in a p53-independent manner. Transcriptomic analyses of PDACs supported a p53-independent role for ARF, with ARF deficiency promoting extracellular matrix, collagen synthesis/assembly, and epithelial–mesenchymal transition gene expression programs. Accordingly, ARF-deficient PDACs displayed extensive remodeling of the tumor microenvironment (TME), associated with collagen deposition, increased tissue stiffness, and higher fibroblast content—hallmarks of aggressive and treatment-resistant PDAC stroma. Together, this study shows how ARF deficiency associated with CDKN2A inactivation sculpts the PDAC TME in a p53-independent fashion. Given the central role of the TME in PDAC progression and therapeutic resistance, these findings may provide insight critical for improving therapeutic interventions for PDAC.Significance:ARF deficiency induced by CDKN2AARF alterations promotes remodeling of the pancreatic cancer microenvironment, which could provide a genotype-specific therapeutic vulnerability to improve outcomes of pancreatic cancer patients.See related commentary by Destefanis and Mulvaney, p. 3101
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
The CDKN2A locus, which is frequently deleted in pancreatic ductal adenocarcinoma (PDAC), encodes two tumor suppressors, ARF and INK4A, that may influence tumorigenesis through distinct mechanisms. Distinguishing their individual contributions to cancer could help improve the understanding of PDAC pathogenesis and potentially uncover targetable vulnerabilities. Moreover, whereas ARF is known to enhance p53 function, defining its p53-independent activities could elucidate new processes that drive PDAC development. In this study, we sought to understand ARF function in PDAC suppression. Analysis of gene expression and mutational patterns in human PDAC TCGA data indicated that CDKN2AARF and CDKN2AINK4A are commonly both affected by point mutations and/or deletions, suggesting that their combined inactivation contributes to PDAC development. In genetically engineered mouse models, Arf inactivation accelerated KRASG12D-driven PDAC development, both in the presence and absence of Trp53, demonstrating that ARF is a PDAC-suppressor and can act in a p53-independent manner. Transcriptomic analyses of PDACs supported a p53-independent role for ARF, with ARF deficiency promoting extracellular matrix, collagen synthesis/assembly, and epithelial–mesenchymal transition gene expression programs. Accordingly, ARF-deficient PDACs displayed extensive remodeling of the tumor microenvironment (TME), associated with collagen deposition, increased tissue stiffness, and higher fibroblast content—hallmarks of aggressive and treatment-resistant PDAC stroma. Together, this study shows how ARF deficiency associated with CDKN2A inactivation sculpts the PDAC TME in a p53-independent fashion. Given the central role of the TME in PDAC progression and therapeutic resistance, these findings may provide insight critical for improving therapeutic interventions for PDAC.Significance:ARF deficiency induced by CDKN2AARF alterations promotes remodeling of the pancreatic cancer microenvironment, which could provide a genotype-specific therapeutic vulnerability to improve outcomes of pancreatic cancer patients.See related commentary by Destefanis and Mulvaney, p. 3101
- 19 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 656, 218666
DNA methylation-based classification uncovers acinar and ductal origins for KPC-derived PDAC cell lines
- 19 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 656, 218666
DNA methylation-based classification uncovers acinar and ductal origins for KPC-derived PDAC cell lines
- 14 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (13) , OF1-OF14
Inactivation of CDKN2A ARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
The CDKN2A locus, which is frequently deleted in pancreatic ductal adenocarcinoma (PDAC), encodes two tumor suppressors, ARF and INK4A, that may influence tumorigenesis through distinct mechanisms. Distinguishing their individual contributions to cancer could help improve the understanding of PDAC pathogenesis and potentially uncover targetable vulnerabilities. Moreover, whereas ARF is known to enhance p53 function, defining its p53-independent activities could elucidate new processes that drive PDAC development. In this study, we sought to understand ARF function in PDAC suppression. Analysis of gene expression and mutational patterns in human PDAC TCGA data indicated that CDKN2AARF and CDKN2AINK4A are commonly both affected by point mutations and/or deletions, suggesting that their combined inactivation contributes to PDAC development. In genetically engineered mouse models, Arf inactivation accelerated KRASG12D-driven PDAC development, both in the presence and absence of Trp53, demonstrating that ARF is a PDAC-suppressor and can act in a p53-independent manner. Transcriptomic analyses of PDACs supported a p53-independent role for ARF, with ARF deficiency promoting extracellular matrix, collagen synthesis/assembly, and epithelial–mesenchymal transition gene expression programs. Accordingly, ARF-deficient PDACs displayed extensive remodeling of the tumor microenvironment (TME), associated with collagen deposition, increased tissue stiffness, and higher fibroblast content—hallmarks of aggressive and treatment-resistant PDAC stroma. Together, this study shows how ARF deficiency associated with CDKN2A inactivation sculpts the PDAC TME in a p53-independent fashion. Given the central role of the TME in PDAC progression and therapeutic resistance, these findings may provide insight critical for improving therapeutic interventions for PDAC. Significance: ARF deficiency induced by CDKN2AARF alterations promotes remodeling of the pancreatic cancer microenvironment, which could provide a genotype-specific therapeutic vulnerability to improve outcomes of pancreatic cancer patients.
- 14 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (13) , OF1-OF14
Inactivation of CDKN2A ARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment
The CDKN2A locus, which is frequently deleted in pancreatic ductal adenocarcinoma (PDAC), encodes two tumor suppressors, ARF and INK4A, that may influence tumorigenesis through distinct mechanisms. Distinguishing their individual contributions to cancer could help improve the understanding of PDAC pathogenesis and potentially uncover targetable vulnerabilities. Moreover, whereas ARF is known to enhance p53 function, defining its p53-independent activities could elucidate new processes that drive PDAC development. In this study, we sought to understand ARF function in PDAC suppression. Analysis of gene expression and mutational patterns in human PDAC TCGA data indicated that CDKN2AARF and CDKN2AINK4A are commonly both affected by point mutations and/or deletions, suggesting that their combined inactivation contributes to PDAC development. In genetically engineered mouse models, Arf inactivation accelerated KRASG12D-driven PDAC development, both in the presence and absence of Trp53, demonstrating that ARF is a PDAC-suppressor and can act in a p53-independent manner. Transcriptomic analyses of PDACs supported a p53-independent role for ARF, with ARF deficiency promoting extracellular matrix, collagen synthesis/assembly, and epithelial–mesenchymal transition gene expression programs. Accordingly, ARF-deficient PDACs displayed extensive remodeling of the tumor microenvironment (TME), associated with collagen deposition, increased tissue stiffness, and higher fibroblast content—hallmarks of aggressive and treatment-resistant PDAC stroma. Together, this study shows how ARF deficiency associated with CDKN2A inactivation sculpts the PDAC TME in a p53-independent fashion. Given the central role of the TME in PDAC progression and therapeutic resistance, these findings may provide insight critical for improving therapeutic interventions for PDAC. Significance: ARF deficiency induced by CDKN2AARF alterations promotes remodeling of the pancreatic cancer microenvironment, which could provide a genotype-specific therapeutic vulnerability to improve outcomes of pancreatic cancer patients.